[1] Lee JJ.Options for second-line treatment in metastatic colorectal cancer[J].Clin Adv Hematol Oncol,2016,14(1):46-54. [2] Zygulska AL,Krzemieniecki K.Salvage chemotherapy in metastatic colorectal cancer with the combination of capecitabine and mitomycin C[J].Neoplasma,2015,62(5):793-797. [3] Grothey A.Colorectal cancer in 2014: progress in defining first-line and maintenance therapies[J].Hubbard JM Nat Rev Clin Oncol,2015,12(2):73-74. [4] Bitossi R, Sculli CM, Tampellini M,et al.Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients[J].Anticancer Res,2008, 28(5B):3055-3060. [5] Jiménez-Fonseca P, Solis MP, Garrido M,et al.Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer[J].Clin Transl Oncol,2015,17(5):384-392. [6] Spindler KL,Pallisgaard N,Andersen RF,et al.Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase Ⅱ and translational research study[J].Anticancer Res,2014, 34(2):845-850.
2017, Vol. 34 
